API
< Back to all clusters
[HEALTH] · United Kingdom · 2 sources

started · updated

Scotland reports geographical variation in GLP-1 drug prescribing

A report by the Association of the British Pharmaceutical Industry (ABPI) has identified “substantial geographical variation” in the prescribing of GLP-1 and GIP/GLP-1 medications, such as Ozempic and Mounjaro, across NHS Scotland health boards.

While NHS prescribing for these drugs has seen strong growth, the study found differences between boards that cannot be fully explained by patient need. The research, which tracked prescribing following approval by the Scottish Medicines Consortium (SMC), suggests a need for a more coordinated implementation approach led by the Scottish Government and NHS Scotland leadership.

Although these medications are approved for both weight loss and treating inadequately controlled type 2 diabetes, the report noted that most NHS prescriptions are currently for type 2 diabetes. Use for obesity remains limited within the NHS, with 71% of Scottish respondents taking weight-loss medication in the last year obtaining it through private providers rather than the NHS.

Entities

Association of the British Pharmaceutical Industry · NHS Scotland · Scotland · Scottish Medicines Consortium